Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms.

In 2008, total sales of prescription and OTC smoking cessation products amounted to over $3bn worldwide. Smoking Cessation, 2009-2024 forecasts how this market will grow and develop from 2009 to 2024. This report predicts that launches of nicotine vaccines from 2011 onwards will alleviate some of the currently-unmet needs in smoking cessation. Which nicotine vaccine will be first to market? Smoking Cessation, 2009-2024 answers that question and many others, providing expert-opinion and analyses on the development of smoking cessation products of many types, dealing with both pipeline and marketing developments in the sector. For specific insight into nicotinic receptor ligands see UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009

During the next 15 years, overall growth in the world smoking cessation market will be increasingly contributed by the BRIC (Brazil, Russia, India and China) group of countries. Nearly half of the world’s smokers live in BRIC areas, yet those country markets yielded low per capita smoking cessation revenues in 2008. Smoking Cessation, 2009-2024 analyses the BRIC smoking cessation markets and their prospects for future growth, revealing how their market shares will increase from 2009 to 2024. This report also analyses the current-leading markets in North America, Europe and Asia in detail.

Smoking Cessation, 2009-2024 is a comprehensive analysis of the world smoking cessation market, compiled using a wealth of research tools – including interviews with key opinion-leaders, examination of company reports, press-releases and filings, use of commercial databases and analyses of unmet needs and market opportunities. Highlights include:

• Forecasts for the world smoking cessation market, leading therapy types, brands and individual country markets.
• Detailed examination and market forecasts for the individual country smoking cessation markets in the US, Canada, Brazil, the UK, France, Germany, Sweden, Russia, Japan, China and India.
• Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the industry.
• In-depth analysis of the pharmacological pipeline for new smoking cessation products.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for smoking cessation therapies from 2009-2024, including predicted revenues, growth rates and other key metrics.
• To discover the fate of Pfizer’s Chantix/Champix, in light of recent safety-concerns.
• To identify key pipeline developments and up-and-coming products.
• To discover the forces, restraints, competition and opportunities influencing each of the separate areas of the smoking cessation market, including nicotine replacement therapies, Pfizer’s Chantix/Champix and bupropion drugs.
• To find out where the market is heading - both technologically and commercially - from the present onwards.

The majority of smokers worldwide do not have full access to smoking cessation therapies. Smoking prevalence is increasing overall, with increases mainly contributed by developing countries. Adverse health effects and the high economic costs associated with tobacco smoking are encouraging increasingly-stringent smoking legislation and encouraging governmental spending on anti-smoking aids. From 2009 to 2024, the continuing introduction and implementation of tobacco-control policies will accelerate, further encouraging people to stop smoking, in turn increasing the use of smoking cessation products. This report demonstrates how the smoking cessation market will expand worldwide as a result.

Smoking Cessation, 2009-2024 shows that new smoking cessation drugs will enjoy commercial success only if these are clearly tolerable and more-effective in practice, easily accessible, backed by innovative marketing campaigns and delivered in combination with behavioural support programmes. Smoking cessation drugs with these characteristics will overcome regulatory hurdles and achieve adequate reimbursement from cost-conscious healthcare providers.

This report is essential reading for everybody involved in the smoking cessation market, revealing prospects for both existing competitors and potential market entrants, from the present onwards.

1 Executive Summary

2 Introduction to Smoking Cessation

• 2.1 Tobacco
  • 2.1.1 Types of Tobacco Consumption
  • 2.1.2 Tobacco Use is a Global Pandemic
• 2.2 Nicotine Addiction
• 2.3 Smoking Cessation
  • 2.3.1 Why is it Difficult to Stop Smoking?
  • 2.3.2 Methods for Smoking Cessation
  • 2.3.3 Pharmacological Smoking Cessation Products
• 2.4 Nicotine Replacement Therapy (NRT)
  • 2.4.1 Nicorette NRT (Johnson & Johnson/Takeda)
  • 2.4.2 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK)
  • 2.4.3 Novartis NRT Brands
  • 2.4.4 Other NRT Manufacturers
• 2.5 Bupropion
  • 2.5.1 Zyban (GSK/Biovail)
  • 2.5.2 Generic Bupropion Drugs
• 2.6 Chantix/Champix (varenicline, Pfizer)
• 2.7 Off-Label Drug Prescribing for Smoking Cessation

3 The Global Smoking Cessation Market

• 3.1 The Global Smoking Cessation Market, 2007-2008
  • 3.1.1 Smoking Cessation Market Value, 2007-2008
  • 3.1.2 Leading Smoking Cessation Product Types, 2007-2008
  • 3.1.3 Leading Smoking Cessation Brands, 2007
  • 3.1.4 Leading Manufacturers of Smoking Cessation Products, 2007
• 3.2 Global Smoking Cessation Market Forecasts, 2009-2024
  • 3.2.1 Growth in the Smoking Cessation Market, 2009-2024
  • 3.2.2 Emerging Markets and the Fate of Chantix: Smoking Cessation Market Forecast, 2009-2014
  • 3.2.3 What are the Prospects for the Smoking Cessation Market during 2014-2019?
  • 3.2.4 During 2019-2024 the Smoking Cessation Market Growth Will Accelerate
  • 3.2.5 Smoking Cessation Product Type Sales Forecast, 2009-2024
  • 3.2.6 Nicotine Replacement Therapies Sales Forecast, 2009-2024
  • 3.2.7 Chantix/Champix Sales Forecast, 2009-2024
  • 3.2.8 Bupropion Smoking Cessation Drugs Sales Forecast, 2009-2024

4 Leading Eight Smoking Cessation Country Markets

• 4.1 Eight Smoking Cessation Markets Had 74% of 2007 World Sales
• 4.2 Leading Eight Smoking Cessation Country Markets Forecast, 2009-2024
• 4.3 The US Smoking Cessation Market
  • 4.3.1 Smoking Prevalence Declining in US
  • 4.3.2 Availability and Reimbursement of Smoking Cessation Aids in the US
  • 4.3.3 US Smoking Cessation Market Revenue, 2007-2008
  • 4.3.4 Leading US Smoking Cessation Product Types, 2007-2008
  • 4.3.5 Is there Scope for US Smoking Cessation Market Expansion?
  • 4.3.6 US Smoking Cessation Market Forecast, 2009-2024
  • 4.3.7 US Nicotine Replacement Therapies Sales Forecast, 2009-2024
  • 4.3.8 Chantix (US) Sales Forecast, 2009-2024
• 4.4 The Canadian Smoking Cessation Market
  • 4.4.1 Current Smoking Prevalence in Canada
  • 4.4.2 Availability and Reimbursement of Smoking Cessation Products in Canada
  • 4.4.3 Canadian Smoking Cessation Market Revenues and Market Shares, 2007
  • 4.4.4 Factors Affecting the Canadian Smoking Cessation Market
  • 4.4.5 Canadian Smoking Cessation Market Forecast, 2009-2024
• 4.5 The UK Smoking Cessation Market
  • 4.5.1 Tobacco Use in the UK
  • 4.5.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT
  • 4.5.3 The UK is Europe’s Largest Smoking Cessation Market
  • 4.5.4 UK Government Anti-Smoking Legislation Lifts Market
  • 4.5.5 UK Smoking Cessation Market Forecast, 2009-2024
• 4.6 The French Smoking Cessation Market
  • 4.6.1 French Smoking Prevalence
  • 4.6.2 The French Smoking Cessation Market, 2007-2008
  • 4.6.3 Leading Product Types in the French Smoking Cessation Market, 2007
  • 4.6.4 French Government’s Provision of Smoking Cessation Aid Better than in Many Other European Countries
  • 4.6.5 French Smoking Cessation Market Forecast, 2009-2024
• 4.7 The Swedish Smoking Cessation Market
  • 4.7.1 Snus in Sweden Increasing in Prevalence
  • 4.7.2 The Swedish Smoking Cessation Market, 2007-2008
  • 4.7.3 Leading Product Types in the Swedish Smoking Cessation Market, 2007
  • 4.7.4 Swedish Smoking Cessation Market Forecast, 2009-2024
• 4.8 The German Smoking Cessation Market
  • 4.8.1 The German Smoking Cessation Market, 2007-2008
  • 4.8.2 Leading Product Types in the German Smoking Cessation Market, 2007
  • 4.8.3 Factors Holding Back the German Smoking Cessation Market
  • 4.8.4 German Smoking Cessation Market Forecast, 2009-2024
• 4.9 The Australian Smoking Cessation Market
  • 4.9.1 The Australian Smoking Cessation Market, 2007-2008
  • 4.9.2 Leading Australian Smoking Cessation Product Types, 2007
  • 4.9.3 Australian Smoking Cessation Market Forecast, 2009-2024
• 4.10 The Japanese Smoking Cessation Market
  • 4.10.1 Japan has an Undeveloped Smoking Cessation Market
  • 4.10.2 The Japanese Smoking Cessation Market, 2007-2008
  • 4.10.3 Japanese Smoking Cessation Market Forecast, 2009-2024

5 BRIC Smoking Cessation Markets

• 5.1 Greatest Market Growth Predicted in BRIC
• 5.2 The Brazilian Smoking Cessation Market
  • 5.2.1 Brazilian Smoking Prevalence
  • 5.2.2 The Brazilian Government has Set Smoking Cessation as a Health Priority
  • 5.2.3 The Brazilian Smoking Cessation Market, 2007
  • 5.2.4 Brazilian Smoking Cessation Market Forecast, 2009-2024
• 5.3 The Russian Smoking Cessation Market
  • 5.3.1 High Smoking Prevalence in Russia
  • 5.3.2 The Russian Smoking Cessation Market, 2007-2008
  • 5.3.3 Russia Signed the Framework Convention on Tobacco Control in 2008
  • 5.3.4 Russian Smoking Cessation Market Forecast, 2009-2024
• 5.4 The Indian Smoking Cessation Market
  • 5.4.1 Tobacco in India is Both Smoked and Chewed
  • 5.4.2 The Indian Smoking Cessation Market, 2007-2008
  • 5.4.3 Indian Smoking Cessation Market Still in its Infancy
  • 5.4.4 Prospects for Growth of the Indian Smoking Cessation Market
  • 5.4.5 Indian Smoking Cessation Market Forecast, 2009-2024
• 5.5 The Chinese Smoking Cessation Market
  • 5.5.1 More than 5 Billion Cigarettes are Smoked in China Every Day
  • 5.5.2 The Chinese Smoking Cessation Market, 2007-2008
  • 5.5.3 The Chinese Smoking Cessation Market is Undeveloped
  • 5.5.4 Smoking Cessation Market Prospects in China and Hong Kong
  • 5.5.5 Chinese Smoking Cessation Market Forecast, 2009-2024

6 Issues Affecting the Smoking Cessation Market

• 6.1 SWOT Analysis for the Smoking Cessation Market
• 6.2 Strengths of the Smoking Cessation Industry
  • 6.2.1 Innovation in Smoking Cessation Therapies
  • 6.2.2 Innovative Marketing Techniques
  • 6.2.3 Manufacturers are Providing Support Plans in Combination with Pharmacotherapy
  • 6.2.4 OTC-Switching
• 6.3 Weaknesses of the Smoking Cessation Industry
  • 6.3.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
  • 6.3.2 Currently-Marketed Smoking Cessation Therapies Have High Relapse Rate
• 6.4 Opportunities for the Smoking Cessation Market
  • 6.4.1 Smoking is Prevalent Worldwide and Slowly Increasing
  • 6.4.2 Countries with Untapped Smoking Cessation Market Potential
  • 6.4.3 Growth of Emerging-Economy Smoking Cessation Markets
  • 6.4.4 Health Effects of Tobacco
  • 6.4.5 Economic Impact of Tobacco
  • 6.4.6 Framework Convention on Tobacco Control (FCTC)
  • 6.4.7 Government Smoking Cessation Programmes
  • 6.4.8 Increasing Tobacco Taxes
  • 6.4.9 Smoking Bans
  • 6.4.10 Warning Information on Tobacco Products
  • 6.4.11 Bans on Tobacco Advertising, Promotion and Sponsorship
• 6.5 Threats to the Smoking Cessation Industry
  • 6.5.1 Concern over Side-Effects of Smoking Cessation Drugs
    • 6.5.1.1 Champix/Chantix Showed Potential, but then Hit by Safety Concerns
    • 6.5.1.2 Side-Effect Concerns for NRT and Bupropion
    • 6.5.1.3 The Result of Side-Effect Concerns
  • 6.5.2 Lack of Reimbursement for Smoking Cessation Therapies
  • 6.5.3 Traditional Smokeless Tobacco
    • 6.5.3.1 Snus and Gutkha
    • 6.5.3.2 A Possible Impact of Greater Smokeless Tobacco Prevalence
  • 6.5.4 The E-Cigarette
    • 6.5.4.1 What are E-Cigarettes?
    • 6.5.4.2 The E-Cigarette Market
    • 6.5.4.3 E-Cigarettes Will Revolutionise the Face of Tobacco Smoking and Could Pose a Threat to the Smoking Cessation Market
    • 6.5.4.4 Will E-Cigarettes Compete with Smoking Cessation Therapies?

7 The Smoking Cessation Pipeline

• 7.1 Novel Vaccines Will Target Nicotine Addiction
  • 7.1.1 NicVAX (Nabi Biopharmaceuticals)
  • 7.1.2 NIC002 (Cytos Biotechnology/Novartis)
  • 7.1.3 TA-NIC (Celtic Pharma)
  • 7.1.4 Niccine (Independent Pharmaceutica)
• 7.2 Expert Opinion on Nicotine Vaccines from Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals
  • 7.2.1 Vaccines in the Pipeline for Nicotine Addiction
  • 7.2.2 NicVAX Nicotine Vaccine
  • 7.2.3 Other Nicotine Vaccines
• 7.3 Monoamine Oxidase Inhibitors
  • 7.3.1 EVT 302 (Evotec)
  • 7.3.2 Selegiline (National Institute on Drug Abuse [NIDA])
• 7.4 Glycine Antagonists
• 7.5 Opiate Antagonists and Agonists
• 7.6 Dopamine D3 Antagonists
• 7.7 Nicotinic Ligands
• 7.8 Dopamine Uptake Inhibitors
• 7.9 Cannabinoid Receptor 1 Antagonists

8 Conclusions

• 8.1 Smoking is a Global Pandemic of Enormous Proportions
• 8.2 Smoking Cessation
• 8.3 The Smoking Cessation Market in 2008
• 8.4 World Smoking Cessation Market, 2009-2024
• 8.5 Leading Eight Smoking Cessation Markets and BRIC

List of Tables

• Table 2.1 Nicotine Replacement Therapy Types
• Table 2.2 Nicorette NRT Brands (Johnson & Johnson/Takeda)
• Table 2.3 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK)
• Table 2.4 Novartis NRT Brands
• Table 2.5 Other NRT Brands
• Table 2.6 Key Drugs Prescribed Off-Label for Smoking Cessation
• Table 3.1 World Smoking Cessation Market Sales, 2007-2008
• Table 3.2 Leading Smoking Cessation Product Types, 2007-2008
• Table 3.3 Leading Smoking Cessation Brands, 2007
• Table 3.4 Leading Manufacturers of Smoking Cessation Products, 2007
• Table 3.5 World Smoking Cessation Market Forecast, 2009-2014
• Table 3.6 World Smoking Cessation Market Forecast, 2015-2024
• Table 3.7 Smoking Cessation Product Type Sales Forecast, 2009-2014
• Table 3.8 Smoking Cessation Product Type Sales Forecast, 2015-2024
• Table 4.1 Leading Eight Smoking Cessation Markets, 2007-2008
• Table 4.2 Smoking Cessation Country Markets Forecasts, 2009-2014
• Table 4.3 Smoking Cessation Country Markets Forecasts, 2015-2024
• Table 4.4 US Smoking Cessation Market Sales, 2007-2008
• Table 4.5 Leading US Smoking Cessation Product Types, 2007-2008
• Table 4.6 US Smoking Cessation Product Type Sales Forecast, 2009-2014
• Table 4.7 US Smoking Cessation Product Type Sales Forecast, 2015-2024
• Table 4.8 Leading Canadian Smoking Cessation Product Types, 2007
• Table 4.9 Leading UK Smoking Cessation Product Types, 2007
• Table 4.10 Leading French Smoking Cessation Product Types, 2007
• Table 4.11 Leading Swedish Smoking Cessation Product Types, 2007
• Table 4.12 Leading German Smoking Cessation Product Types, 2007
• Table 4.13 Leading Australian Smoking Cessation Product Types, 2007
• Table 5.1 BRIC Smoking Cessation Markets, 2007 & 2024
• Table 6.1 SWOT Chart for the Smoking Cessation Market
• Table 6.2 Smoking Prevalence and Smoking Cessation Revenue Per Smoker in Twenty Countries with Highest Number of Smokers
• Table 7.1 Key Smoking Cessation Pipeline Products
• Table 8.1 Smoking Cessation Country Markets 2008 Sales and CAGR, 2008-2024

List of Figures

• Figure 3.1 Leading Smoking Cessation Product Types, 2007
• Figure 3.2 Leading Smoking Cessation Brands, 2007
• Figure 3.3 Leading Manufacturers of Smoking Cessation Products, 2007
• Figure 3.4 Global Smoking Cessation Market Forecast, 2009-2024
• Figure 3.5 Smoking Cessation Product Type Sales Forecast, 2009-2024
• Figure 3.6 Smoking Cessation Product Type Sales & Market Share, 2007, 2014, 2019 and 2024
• Figure 3.7 Nicotine Replacement Therapies Sales Forecast, 2009-2024
• Figure 3.8 Chantix/Champix Sales Forecast, 2009-2024
• Figure 4.1 2007 Smoking Cessation Market Share by Country
• Figure 4.2 2014 Smoking Cessation Market Share by Country
• Figure 4.3 2019 Smoking Cessation Market Share by Country
• Figure 4.4 2024 Smoking Cessation Market Share by Country
• Figure 4.5 Leading US Smoking Cessation Product Types, 2007
• Figure 4.6 US Smoking Cessation Market Forecast, 2009-2024
• Figure 4.7 US Nicotine Replacement Therapies Sales Forecast, 2009-2024
• Figure 4.8 Chantix (US) Sales Forecast, 2009-2024
• Figure 4.9 Canadian Smoking Cessation Market Forecast, 2009-2024
• Figure 4.10 UK Smoking Cessation Market Forecast, 2009-2024
• Figure 4.11 French Smoking Cessation Market Forecast, 2009-2024
• Figure 4.12 Swedish Smoking Cessation Market Forecast, 2009-2024
• Figure 4.13 German Smoking Cessation Market Forecast, 2009-2024
• Figure 4.14 Australian Smoking Cessation Market Forecast, 2009-2024
• Figure 4.15 Japanese Smoking Cessation Market Forecast, 2009-2024
• Figure 5.1 BRIC Smoking Cessation Markets CAGR, 2008-2024
• Figure 5.2 Brazilian Smoking Cessation Market Forecast, 2009-2024
• Figure 5.3 Russian Smoking Cessation Market Forecast, 2009-2024
• Figure 5.4 Indian Smoking Cessation Market Forecast, 2009-2024
• Figure 5.5 Chinese Smoking Cessation Market Forecast, 2009-2024
• Figure 6.1 Twenty Countries with Highest Number of Tobacco Smokers
• Figure 8.1 Global Smoking Cessation Market Forecast, 2009-2024